BTG Live Discussion

johnymccarthy 03 Sep 2019

Cash Take over of BTG at £8.40 per share by Bravo Bidco I should have waited just one more day!

johnymccarthy 02 Sep 2019

Cash Take over of BTG at £8.40 per share by Bravo Bidco The deal has now gone through but as yet I have not seen any money! Seems to be taking rather a long time, I have shares with Selftrade also share certificates and would like to re-invest, anyone been paid yet?

johnymccarthy 09 May 2019

Cash Take over of BTG at £8.40 per share by Bravo Bidco According to the documents I have seen 20th August is the latest date which the arrangement can take place. Therefore any time between then and now is possible. 6 to 12 months is quite normal for these sort of transaction to take place. It should be sometime in the 2019/20 tax year!!!

jgrjgr 24 Apr 2019

Cash Take over of BTG at £8.40 per share by Bravo Bidco When do we expect to get the dosh??

lesberkeley 21 Nov 2018

Cash Take over of BTG at £8.40 per share by Bravo Bidco It’s only a 13% premium over what it was a year or so ago, but I’m happy to cash in. Fortunately I topped up recently with money from the sale of my remaining Bitcoins. Hallelujah ! Ps . also closed shorts on that wretched company BP - nice earner there too!

johnymccarthy 21 Nov 2018

Cash Take over of BTG at £8.40 per share by Bravo Bidco ‘a budding pharma facilitated’ is hardly an appropriate description of BTG. I invested in the previous century and have for some inexplicable reason kept the faith. No dividend, lots of buyouts, huge salaries, promises promises promises, share price up and down like a wh…s dr…s, I cannot say that I am sorry to see the back of BTG.

Denis_Filby 20 Nov 2018

Cash Take over of BTG at £8.40 per share by Bravo Bidco For once Dave you are right to say Be Happy. It has been a long ride and with a lot of horses.

frog_in_a_tree 20 Nov 2018

Cash Take over of BTG at £8.40 per share by Bravo Bidco Sad that I will be losing my holding in BTG. At least I will have made a very decent profit on my holding just like I did with GW Pharma. This looks like the same story…an American takeover of a budding pharma facilitated, no doubt, by a Brexit induced sterling devaluation. Cheers, Frog in a tree

d_gaser 20 Nov 2018

Cash Take over of BTG at £8.40 per share by Bravo Bidco 20 November 2018 RECOMMENDED CASH OFFER for BTG plc (“BTG”) by Bravo Bidco Limited (“Bravo Bidco”) a newly incorporated entity indirectly wholly-owned by Boston Scientific Corporation (“Boston Scientific”) intended to be effected by means of a scheme of arrangement under Part 26 of the Companies Act Summary •The Boards of Boston Scientific, Bravo Bidco and BTG are pleased to announce that they have reached agreement on the terms of a recommended cash offer by Bravo Bidco for the acquisition of the entire issued and to be issued ordinary share capital of BTG (the “Acquisition”). The Acquisition is intended to be effected by means of a scheme of arrangement under Part 26 of the Companies Act (the “Scheme”). •Under the terms of the Acquisition, BTG Shareholders will be entitled to receive: for each BTG Share: 840 pence in cash (the “Offer Price”) At last we have got back to that figure of £8.40 per share , Im not surprised as I had a feeling this was coming when they changed the reporting from pounds to dollars BE Happy DAVE 

d_gaser 04 Oct 2018

BTG update ending 30 sept, shows bigger than expected growth This is a very welcomed up date, at last we seem to be moving in the right direction . Be Happy Dave RNS Number : 9134C BTG PLC 04 October 2018 BTG plc: close period update Good first half performance, updating full year sales growth guidance London, UK, 4 October 2018: BTG plc (LSE: BTG), the global healthcare company, provides the following update for the six months ended 30 September 2018. Louise Makin, BTG’s CEO, commented: “I am pleased to report positive momentum across all areas of the business. We have delivered good product sales growth during the first half, driven by the performance of Interventional Medicine. With the acquisition of Novate Medical and today’s confirmation of our commitment to Varithena®, we now have a multi-product Vascular portfolio. As a result of the inclusion of Varithena® we are updating our guidance for combined Oncology and Vascular CER1 product sales growth to 15-17% for the year. Pharmaceuticals performed well in the first half and we now expect sales for the year to be around the upper end of our guidance range. By continuing to invest in product innovation, clinical data, geographic expansion and acquisitions, we are developing leading positions in attractive growth markets and creating significant long-term value for shareholders.” Product sales Interventional Medicine The very good performance in Interventional Medicine was driven by strong growth in TheraSphere® and the cryoablation products, with good growth in EKOS. BTG today confirms its commitment to Varithena®. Progress since dedicated CPT reimbursement codes became effective in January 2018 has been positive. Varithena® is expected to become profitable during the 2019/20 financial year and to have peak sales potential in the high tens of millions of dollars. Its sales will be included within the Vascular product sales line going forwards. With the addition of Varithena® and Novate Medical to EKOS and the Crossing Devices, BTG now has a multi-product Vascular business. Following the US Food & Drug Administration’s decision in August 2018 not to approve the Premarket Approval application, BTG continues to review options for PneumRx, which include partnering with or sale to a third party. Pharmaceuticals A better than expected performance in Pharmaceuticals was driven by DigiFab® and Voraxaze®, with a good performance from CroFab®. Updated product sales guidance CER product sales growth for the combined Oncology and Vascular portfolios, including Varithena®, is now expected to be 15-17% for the full year. In Pharmaceuticals, following a good first half, BTG now expects full year sales to be around the upper end of the guidance range of flat-to-single digit CER decline. BTG’s Interim Results will be published on 13 November 2018. For further information contact:

d_gaser 21 Sep 2018

Btg lauunches ICEFx Cryoablation sydtem It’s good to see BTG are still producing some new equipment ,even if its just an update .Hopefully this will help sales and mark up BE Happy Dave BTG launches ICEfx Cryoablation System London Friday, September 21, 2018, 090 Hrs [IST] BTG plc, a global specialist healthcare company, announced the global launch of the ICEfx Cryoablation System. ICEfx, an evolution of the existing Visual ICE system, offers predictable, reliable performance with seamless therapy delivery and exceptional ease of technical operation. This compact and powerful console is designed for interventional radiologists who want to offer their patients state-of-the-art, minimally invasive treatment options. It allows physicians to provide safe and efficient cryoablation procedures, facilitating precise and effective treatment without the need for surgery or repeated radiation treatments. “The ICEfx Cryoablation System is a new, more compact design that simplifies the procedure through a set of user-friendly on-screen prompts” said Dr. AJ Gunn, interventional radiologist at University of Alabama, Birmingham. “It is easy for my technicians to set up, operate, and shut down. Importantly, this updated version is designed to work with the current line of BTG cryoablation probes, meaning that physicians can still create the reliable ablation zones they have come to expect.” Peter Pattison, head of interventional oncology at BTG commented: “We continue to invest in both new product innovations and clinical research. Building on our commitment in Interventional Oncology, BTG has added the most advanced cryoablation technology to its portfolio of minimally invasive therapies and is currently supporting a number of active clinical research studies in bone, kidney, lung, pain and prostate. We strive to provide health care professionals with easy access to innovative product choices, our BTG IO portfolio allows them to select and tailor each clinical solution to match a specific patient need.”

d_gaser 10 Sep 2018

BTG buys BTG has paid $20 million in cash to buy Novate, and may pay a further $130 million depending on the device hitting certain sales-related milestones, the UK company said on Friday. BTG[link] BE HAPPY Dave

johnymccarthy 19 Aug 2018

BTG 5% lift on Friday 17th If anyone is still here! Any idea’s why the 5% rise on Friday? Also I think I will be giving up completely on ii, is there an equal alternative to the original discussion board?

d_gaser 09 Aug 2018

BTG receive –Non approvable letter from the US FDA for ELEVAIR™ BTG receive –Non approvable letter from the US FDA for ELEVAIR™ London, UK, 9 August 2018: BTG plc (LSE: BTG), the global specialist healthcare company, today announces that PneumRx has received confirmation from the US Food and Drug Administration (FDA) that the Premarket Approval (PMA) application for its ELEVAIR™ Endobronchial Coil System for the treatment of people with severe emphysema is not approvable. This follows the FDA Advisory Panel’s recommendation in June 2018 not to approve ELEVAIR™. BTG is reviewing options and will provide an update in due course. For further information contact: BTG Andy Burrows, VP Corporate & Investor Relations +44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605 Stuart Hunt, Investor Relations Manager +44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536 Chris Sampson, Corporate Communications Director +44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178 FTI Consulting Ben Atwell/Simon Conway +44 (0)20 3727 1000 About BTG BTG is a global healthcare company focused on Interventional Medicine. Our innovative medical technology helps physicians treat their patients through minimally invasive procedures. We have a growing portfolio of products that advance the treatment of cancer, vascular conditions and severe emphysema. BTG’s Pharmaceuticals business provides products that help patients overexposed to certain medications or toxins. To learn more about BTG, please vis

dano096 30 Jul 2018

Dame Louise Makin faces revolt over free shares, and the lack of new treatments d_gaser: Louise Makin Absolute appalling performance of late, continual series of bad news that suggests complete incompetence. Agree. It’s time for Louise Makin to go.